本帖最后由 老马 于 2013-3-13 13:43 编辑 1 F' ?" Y5 W$ {5 O
6 C' n9 f. o" d* b1 i' w
健择(吉西他滨)+顺铂+阿瓦斯汀
0 D! z% s/ D) V: {2 B. W6 z- L Gemzar +Cisplatin + Avastin
6 J5 J4 f% n9 K& ~( thttp://annonc.oxfordjournals.org/content/21/9/1804.full5 `% m* Q& ^4 a* `) \$ F
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ z- G( k( k- O& V6 ?Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 6 w C. D" n" r
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
! f& ^2 J) [$ o3 I4 ?* d }9 w
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 843)
/ ?$ t* h1 ~- }) `- N( `. \$ D
华为网盘附件:# z( K' Q/ v& q
【华为网盘】ava.JPG
- I7 X" g) F' n% R3 A( S |